Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F9GE
|
|||
| Former ID |
DAP000013
|
|||
| Drug Name |
Dipyridamole
|
|||
| Synonyms |
Agilease; Anginal; Antistenocardin; Apricor; Cardioflux; Cardoxil; Cardoxin; Cerebrovase; Chilcolan; Cleridium; Coribon; Coridil; Coronarine; Corosan; Coroxin; Curantil; Curantyl; Dipiridamol; Dipyramidole; Dipyridamine; Dipyridamol; Dipyridamolum; Dipyridan; Dipyudamine; Dypyridamol; Gulliostin; Justpertin; Kurantil; Miosen; Natyl; Peridamol; Permiltin; Persantin; Persantine; Piroan; Prandiol; Protangix; Stenocardil; Stenocardiol; Stimolcardio; Apotex Brand of Dipyridamole; Ashbourne Brand of Dipyridamole; Belmac Brand of Dipyridamole; Berlin Chemie Brand of Dipyridamole; Boehringer Ingelheim Brand of Dipyridamole; IPRAD Brand of Dipyridamole; Iv Persantine; Novopharm Brand of Dipyridamole; Cleridium 150; D 9766; Prandiol 75; Apo-Dipyridamole; Apo-Dipyridamole Fc; Apo-Dipyridamole Sc; Berlin-Chemie Brand of Dipyridamole; Dipiridamol [INN-Spanish]; Dipyridamolum [INN-Latin]; Novo-Dipiradol; Persantine (TN); RA-8; Usaf Ge-12; Dipyridamole (JP15/USP/INN); Dipyridamole [USAN:INN:BAN:JAN]; Permole, Persantine, Dipyridan, Dipyridamole; 2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1], [2] | |
| Therapeutic Class |
Vasodilator Agents
|
|||
| Company |
FISCHER and ROCH
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H40N8O4
|
|||
| Canonical SMILES |
C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO
|
|||
| InChI |
1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
|
|||
| InChIKey |
IZEKFCXSFNUWAM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 58-32-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
480294, 489152, 612448, 855977, 5052822, 7847368, 7979106, 8149314, 8151978, 10321246, 10528232, 10589644, 11111116, 11111117, 11113358, 11335871, 11361110, 11363898, 11366460, 11369022, 11371244, 11374262, 11377184, 11410079, 11462082, 11466170, 11467290, 11484739, 11485919, 11488788, 11490218, 11492337, 11494818, 12054904, 14811101, 17405027, 22391481, 24277705, 26611713, 26680947, 26747068, 26747069, 26751580, 26751581, 26758633, 29222251, 46487910, 46506292, 47291146, 47291147
|
|||
| ChEBI ID |
CHEBI:4653
|
|||
| ADReCS Drug ID | BADD_D00692 | |||
| SuperDrug ATC ID |
B01AC07
|
|||
| SuperDrug CAS ID |
cas=000058322
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides dorei DSM 17855
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Dipyridamole can be metabolized by Bacteroides dorei DSM 17855 (log2FC = -0.805; p = 0.005). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia hansenii DSM20583
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Dipyridamole can be metabolized by Blautia hansenii DSM20583 (log2FC = -0.58; p = 0.028). | |||
|
Studied Microbe: Clostridium sp.
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Dipyridamole can be metabolized by Clostridium sp. (log2FC = -0.512; p = 0.032). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 5A (PDE5A) | Target Info | Modulator | [4] |
| KEGG Pathway | Purine metabolism | |||
| cGMP-PKG signaling pathway | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | cGMP effects | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4807). | |||
| REF 2 | Inhibition of platelet activation and aggregation. Handb Exp Pharmacol. 2005;(170):443-62. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.